img

Global Non-small Cell Lung Cancer Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Non-small Cell Lung Cancer Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
Non-small Cell Lung Cancer Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Non-small Cell Lung Cancer Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Lung Adenocarcinoma and Squamous Cell Lung Carcinoma are the major drivers for the industry.
The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs market growth during the forecast period. With the increase in the prevalence of lung cancer, the need for a strong pipeline of disease-modifying drugs is also increasing.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non-small Cell Lung Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Segment by Type
Biologics
Small Molecule Targeted Therapy
Chemotherapy
Other

Segment by Application


Lung Adenocarcinoma
Squamous Cell Lung Carcinoma
Large-cell Lung Carcinoma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Non-small Cell Lung Cancer Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Non-small Cell Lung Cancer Drugs introduction, etc. Non-small Cell Lung Cancer Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Non-small Cell Lung Cancer Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Non-small Cell Lung Cancer Drugs
1.1 Non-small Cell Lung Cancer Drugs Market Overview
1.1.1 Non-small Cell Lung Cancer Drugs Product Scope
1.1.2 Non-small Cell Lung Cancer Drugs Market Status and Outlook
1.2 Global Non-small Cell Lung Cancer Drugs Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Non-small Cell Lung Cancer Drugs Market Size by Region (2024-2034)
1.4 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Region (2024-2024)
1.5 Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Non-small Cell Lung Cancer Drugs Market Size (2024-2034)
1.6.1 North America Non-small Cell Lung Cancer Drugs Market Size (2024-2034)
1.6.2 Europe Non-small Cell Lung Cancer Drugs Market Size (2024-2034)
1.6.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size (2024-2034)
1.6.4 Latin America Non-small Cell Lung Cancer Drugs Market Size (2024-2034)
1.6.5 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size (2024-2034)
2 Non-small Cell Lung Cancer Drugs Market by Type
2.1 Introduction
2.1.1 Biologics
2.1.2 Small Molecule Targeted Therapy
2.1.3 Chemotherapy
2.1.4 Other
2.2 Global Non-small Cell Lung Cancer Drugs Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Type (2024-2024)
2.2.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Non-small Cell Lung Cancer Drugs Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Non-small Cell Lung Cancer Drugs Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Non-small Cell Lung Cancer Drugs Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue Breakdown by Type (2024-2034)
3 Non-small Cell Lung Cancer Drugs Market Overview by Application
3.1 Introduction
3.1.1 Lung Adenocarcinoma
3.1.2 Squamous Cell Lung Carcinoma
3.1.3 Large-cell Lung Carcinoma
3.2 Global Non-small Cell Lung Cancer Drugs Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Application (2024-2024)
3.2.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Non-small Cell Lung Cancer Drugs Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Non-small Cell Lung Cancer Drugs Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Non-small Cell Lung Cancer Drugs Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue Breakdown by Application (2024-2034)
4 Non-small Cell Lung Cancer Drugs Competition Analysis by Players
4.1 Global Non-small Cell Lung Cancer Drugs Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2022)
4.3 Date of Key Players Enter into Non-small Cell Lung Cancer Drugs Market
4.4 Global Top Players Non-small Cell Lung Cancer Drugs Headquarters and Area Served
4.5 Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Non-small Cell Lung Cancer Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Products, Services and Solutions
5.1.4 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue (US$ Million) & (2024-2024)
5.1.5 AstraZeneca Recent Developments
5.2 Bristol-Myers Squibb Company
5.2.1 Bristol-Myers Squibb Company Profile
5.2.2 Bristol-Myers Squibb Company Main Business
5.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Products, Services and Solutions
5.2.4 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue (US$ Million) & (2024-2024)
5.2.5 Bristol-Myers Squibb Company Recent Developments
5.3 Eli Lilly and Company
5.3.1 Eli Lilly and Company Profile
5.3.2 Eli Lilly and Company Main Business
5.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Products, Services and Solutions
5.3.4 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue (US$ Million) & (2024-2024)
5.3.5 F. Hoffmann-La Roche Ltd Recent Developments
5.4 F. Hoffmann-La Roche Ltd
5.4.1 F. Hoffmann-La Roche Ltd Profile
5.4.2 F. Hoffmann-La Roche Ltd Main Business
5.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Products, Services and Solutions
5.4.4 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue (US$ Million) & (2024-2024)
5.4.5 F. Hoffmann-La Roche Ltd Recent Developments
5.5 Merck & Co., Inc.
5.5.1 Merck & Co., Inc. Profile
5.5.2 Merck & Co., Inc. Main Business
5.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Products, Services and Solutions
5.5.4 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue (US$ Million) & (2024-2024)
5.5.5 Merck & Co., Inc. Recent Developments
6 North America
6.1 North America Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-small Cell Lung Cancer Drugs Market Dynamics
11.1 Non-small Cell Lung Cancer Drugs Industry Trends
11.2 Non-small Cell Lung Cancer Drugs Market Drivers
11.3 Non-small Cell Lung Cancer Drugs Market Challenges
11.4 Non-small Cell Lung Cancer Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Non-small Cell Lung Cancer Drugs Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Non-small Cell Lung Cancer Drugs Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Non-small Cell Lung Cancer Drugs Market Size Share by Region (2024-2024)
Table 4. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Non-small Cell Lung Cancer Drugs Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Non-small Cell Lung Cancer Drugs Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2024)
Table 9. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2034)
Table 11. North America Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Non-small Cell Lung Cancer Drugs Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Non-small Cell Lung Cancer Drugs Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2024)
Table 24. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2034)
Table 26. North America Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Non-small Cell Lung Cancer Drugs Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2022)
Table 39. Date of Key Players Enter into Non-small Cell Lung Cancer Drugs Market
Table 40. Global Non-small Cell Lung Cancer Drugs Key Players Headquarters and Area Served
Table 41. Non-small Cell Lung Cancer Drugs Product Solution and Service
Table 42. Global Non-small Cell Lung Cancer Drugs Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. AstraZeneca Basic Information List
Table 45. AstraZeneca Description and Business Overview
Table 46. AstraZeneca Non-small Cell Lung Cancer Drugs Products, Services and Solutions
Table 47. Revenue (US$ Million) in Non-small Cell Lung Cancer Drugs Business of AstraZeneca (2024-2024)
Table 48. AstraZeneca Recent Developments
Table 49. Bristol-Myers Squibb Company Basic Information List
Table 50. Bristol-Myers Squibb Company Description and Business Overview
Table 51. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Products, Services and Solutions
Table 52. Revenue (US$ Million) in Non-small Cell Lung Cancer Drugs Business of Bristol-Myers Squibb Company (2024-2024)
Table 53. Bristol-Myers Squibb Company Recent Developments
Table 54. Eli Lilly and Company Basic Information List
Table 55. Eli Lilly and Company Description and Business Overview
Table 56. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Products, Services and Solutions
Table 57. Revenue (US$ Million) in Non-small Cell Lung Cancer Drugs Business of Eli Lilly and Company (2024-2024)
Table 58. Eli Lilly and Company Recent Developments
Table 59. F. Hoffmann-La Roche Ltd Basic Information List
Table 60. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 61. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Products, Services and Solutions
Table 62. Revenue (US$ Million) in Non-small Cell Lung Cancer Drugs Business of F. Hoffmann-La Roche Ltd (2024-2024)
Table 63. F. Hoffmann-La Roche Ltd Recent Developments
Table 64. Merck & Co., Inc. Basic Information List
Table 65. Merck & Co., Inc. Description and Business Overview
Table 66. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Products, Services and Solutions
Table 67. Revenue (US$ Million) in Non-small Cell Lung Cancer Drugs Business of Merck & Co., Inc. (2024-2024)
Table 68. Merck & Co., Inc. Recent Developments
Table 69. North America Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2024) & (US$ Million)
Table 70. North America Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 71. Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2024) & (US$ Million)
Table 72. Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 73. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 74. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2024-2024) & (US$ Million)
Table 75. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2024-2034) & (US$ Million)
Table 76. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Share by Region (2024-2024)
Table 77. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Share by Region (2024-2034)
Table 78. Latin America Non-small Cell Lung Cancer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 79. Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2024) & (US$ Million)
Table 80. Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 81. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 82. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2024) & (US$ Million)
Table 83. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 84. Non-small Cell Lung Cancer Drugs Market Trends
Table 85. Non-small Cell Lung Cancer Drugs Market Drivers
Table 86. Non-small Cell Lung Cancer Drugs Market Challenges
Table 87. Non-small Cell Lung Cancer Drugs Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-small Cell Lung Cancer Drugs Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Non-small Cell Lung Cancer Drugs Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Non-small Cell Lung Cancer Drugs Market Share by Regions: 2022 VS 2034
Figure 4. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Biologics
Figure 11. Global Biologics Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Small Molecule Targeted Therapy
Figure 13. Global Small Molecule Targeted Therapy Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Product Picture of Chemotherapy
Figure 15. Global Chemotherapy Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 16. Product Picture of Other
Figure 17. Global Other Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 18. Global Non-small Cell Lung Cancer Drugs Market Size Share by Type: 2022 & 2034
Figure 19. North America Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2034)
Figure 20. Europe Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2034)
Figure 21. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2034)
Figure 22. Latin America Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2034)
Figure 23. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2024-2034)
Figure 24. Lung Adenocarcinoma Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 25. Squamous Cell Lung Carcinoma Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 26. Large-cell Lung Carcinoma Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 27. Global Non-small Cell Lung Cancer Drugs Market Size Share by Application: 2022 & 2034
Figure 28. North America Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2034)
Figure 29. Europe Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2034)
Figure 30. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2034)
Figure 31. Latin America Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2034)
Figure 32. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2024-2034)
Figure 33. Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 34. Global Top 5 and Top 10 Players Non-small Cell Lung Cancer Drugs Market Share in 2022
Figure 35. North America Non-small Cell Lung Cancer Drugs Market Share by Country (2024-2034)
Figure 36. U.S. Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 37. Canada Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 38. Germany Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 39. France Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 40. U.K. Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 41. Italy Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 42. Russia Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 43. Nordic Countries Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 44. Asia-Pacific Non-small Cell Lung Cancer Drugs Market Share by Region (2024-2034)
Figure 45. China Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 46. Japan Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 47. South Korea Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 48. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 49. India Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 50. Australia Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 51. Latin America Non-small Cell Lung Cancer Drugs Market Share by Country (2024-2034)
Figure 52. Mexico Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 53. Brazil Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 54. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Share by Country (2024-2034)
Figure 55. Turkey Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 56. Saudi Arabia Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 57. UAE Non-small Cell Lung Cancer Drugs Market Size (2024-2034) & (US$ Million)
Figure 58. Bottom-up and Top-down Approaches for This Report